Alnylam Pharmaceuticals (ALNY) Stock Rating Reaffirmed by B. Riley

Alnylam Pharmaceuticals (NASDAQ:ALNY)‘s stock had its “buy” rating reiterated by equities researchers at B. Riley in a research report issued to clients and investors on Friday. They currently have a $205.00 target price on the biopharmaceutical company’s stock. B. Riley’s price target indicates a potential upside of 64.22% from the company’s previous close.

ALNY has been the subject of several other research reports. Barclays increased their target price on shares of Alnylam Pharmaceuticals from $127.00 to $158.00 and gave the stock an “overweight” rating in a report on Wednesday, November 8th. FBR & Co assumed coverage on shares of Alnylam Pharmaceuticals in a report on Monday, October 30th. They set a “buy” rating and a $150.00 target price for the company. Cowen restated an “outperform” rating and set a $151.00 target price (up previously from $117.00) on shares of Alnylam Pharmaceuticals in a report on Friday, November 3rd. Chardan Capital restated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Friday. Finally, Needham & Company LLC restated a “buy” rating and set a $152.00 target price (up previously from $125.00) on shares of Alnylam Pharmaceuticals in a report on Friday, November 3rd. Three analysts have rated the stock with a sell rating, seven have issued a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $121.20.

Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) traded up $0.84 on Friday, reaching $124.83. 881,727 shares of the company traded hands, compared to its average volume of 865,995. Alnylam Pharmaceuticals has a fifty-two week low of $35.98 and a fifty-two week high of $147.63. The firm has a market capitalization of $12,270.00, a PE ratio of -23.78 and a beta of 2.98. The company has a debt-to-equity ratio of 0.14, a current ratio of 9.83 and a quick ratio of 9.83.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.23) by ($0.11). Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The business had revenue of $17.10 million for the quarter, compared to analyst estimates of $28.15 million. During the same quarter in the previous year, the company posted ($1.21) EPS. The business’s revenue for the quarter was up 24.8% compared to the same quarter last year. equities research analysts predict that Alnylam Pharmaceuticals will post -5.29 EPS for the current year.

In other Alnylam Pharmaceuticals news, EVP Akshay Vaishnaw sold 33,666 shares of the stock in a transaction on Monday, October 30th. The shares were sold at an average price of $121.46, for a total value of $4,089,072.36. Following the completion of the sale, the executive vice president now owns 45,201 shares in the company, valued at $5,490,113.46. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Laurie Keating sold 30,000 shares of the stock in a transaction on Friday, December 1st. The shares were sold at an average price of $135.89, for a total transaction of $4,076,700.00. Following the completion of the sale, the senior vice president now owns 41,500 shares of the company’s stock, valued at approximately $5,639,435. The disclosure for this sale can be found here. In the last quarter, insiders sold 274,075 shares of company stock valued at $35,356,089. Corporate insiders own 4.30% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. FMR LLC lifted its stake in shares of Alnylam Pharmaceuticals by 6.3% during the 2nd quarter. FMR LLC now owns 13,723,153 shares of the biopharmaceutical company’s stock worth $1,094,559,000 after buying an additional 815,270 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 13.4% during the 2nd quarter. Vanguard Group Inc. now owns 6,419,508 shares of the biopharmaceutical company’s stock worth $512,020,000 after buying an additional 759,295 shares during the last quarter. BlackRock Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 9.3% during the 2nd quarter. BlackRock Inc. now owns 5,188,191 shares of the biopharmaceutical company’s stock worth $413,811,000 after buying an additional 441,957 shares during the last quarter. Orbimed Advisors LLC lifted its stake in shares of Alnylam Pharmaceuticals by 69.7% during the 3rd quarter. Orbimed Advisors LLC now owns 1,084,800 shares of the biopharmaceutical company’s stock worth $127,453,000 after buying an additional 445,600 shares during the last quarter. Finally, First Trust Advisors LP lifted its stake in shares of Alnylam Pharmaceuticals by 25.3% during the 3rd quarter. First Trust Advisors LP now owns 784,619 shares of the biopharmaceutical company’s stock worth $92,185,000 after buying an additional 158,288 shares during the last quarter. Institutional investors own 88.39% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Alnylam Pharmaceuticals (ALNY) Stock Rating Reaffirmed by B. Riley” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.americanbankingnews.com/2018/01/19/alnylam-pharmaceuticals-alny-stock-rating-reaffirmed-by-b-riley.html.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply